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 Standard treatment protocols for high-grade gliomas, such as glioblastoma 
multiforme (GBM), are highly ineffective due to their inability to eradicate infiltrating 
tumor cells. Improvements in overall survival are likely to be realized only with the 
development of more effective localized therapies capable of eradicating tumor cells in 
the surgical resection margin and beyond. Photochemical internalization (PCI) is a 
localized light-based therapeutic modality that enhances the efficacy of therapeutic 
macromolecules including chemotherapeutic agents such as bleomycin. A number of 
studies have shown that this photodynamic therapy (PDT) - based modality may prove 
effective in the treatment of high-grade gliomas. 
 Three-dimensional multicell human glioma spheroids were used as a tumor model to 
investigate the efficacy of combination therapies consisting of hyperthermia and PCI. 
Hyperthermia has been shown to increase the efficacy of a number of therapies including 
radiation and chemotherapy, however, there have been no studies investigating its utility 
in combination with PCI.  
 The results show that hyperthermia and PCI interact in a synergistic manner over a 
very narrow range of light and temperature levels. In this tumor model, temperatures of 
45 oC resulted in total spheroid death: the exact hyperthermic threshold was estimated to 
be between 42 and 45 oC which provided the rationale for the temperature range 
investigated (40 – 42 oC). No significant differences in growth kinetics and survival were 
observed between PCI- and PDT -exposed spheroids at radiant exposures < 1.5 J cm-2. In 
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contrast, all PDT and PCI spheroids irradiated with 3.0 J cm-2 died, suggesting that the 
useful light range is between 1.5 and 3.0 J cm-2.  
 A relatively low level of synergism was observed between PCI and hyperthermia 
at 1.5 J cm-2 and 40 oC, while a high degree of synergism was found when the two 
modalities were combined at a light level of 2.5 J cm-2 and a temperature of 42 oC. This is 
the first observation of a synergistic interaction between PCI and hyperthermia and, 
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1.1 Malignant Brain Tumors 
Primary malignant brain tumors are uncommon and represent 2 percent of all 
adult cancers in the United States [Iacob 2009].  Gliomas are a non-uniform group of 
tumors in the central nervous system (CNS).  They can be classified as astrocytomas, 
ependymomas, and oligodendrogliomas.  Astrocytomas are the most common and are 
classified as low-grade, while anaplastic astrocytomas and glioblastomas are considered 
grades III and IV, respectively [Iacob 2009].  The most common type is glioblastoma 
multiforme (GBM) which has a dismal prognosis. Although a number of causes have 
been suggested (electromagnetic fields, cellular phones, head trauma, pesticides, N-
nitroso compounds in food products such as cheese and fish,  and genetic syndromes), the 
only proven risk factor for the development of GBM is exposure to high dose ionizing 
radiation [Chandana 2008].  Common symptoms include nausea, vomiting, headaches, 
seizures, personality changes, and neurocognitive deficit.  The American Cancer Society 
estimates there are 12,000 deaths per year in the United States due to brain and nervous 
system cancers.  As shown in Figure 1, the occurrence of primary brain tumors is highest 





Figure 1.  Age-Specific Incidence of Primary Brain and CNS Tumors by Selected 
Histologies; collected 2004-2007. (Adapted from CBTRUS 2011)  
 
Of the estimated 51,000 primary brain tumors diagnosed in the United States 
every year, 36 percent are gliomas. Approximately 50% of gliomas are GBM (Figure 2) 
[Clarke 2010].     
 
Figure 2.  Distribution of all primary brain and CNS gliomas by histology subtypes; 





Starting in 2005, the standard treatment therapy for GBM consists of surgical 
resection followed by chemotherapy with temozolomide and radiation up to 60 Gy.  
Temozolomide (TMZ) is an alkylating agent that attaches an alkyl group to DNA 
resulting in irreparable damage.  The median survival for patients receiving this treatment 
regimen is 14.6 months compared to 12.1 months for patients treated with radiation only 
[Pan 2011].  Even with the combined treatments, the disease almost always recurs 
[Nishikawa 2010].  In many cases, the complete removal of a glioma is not possible due 
to extensive tumor cell infiltration into normal brain. The aim of current treatment 
regimens is to eliminate these infiltrative cells [Iacob 2009].  
Diagnosing a brain tumor starts with imaging, followed by histopathology to 
verify the diagnosis.  Recent advances in brain imaging techniques have resulted in 
improved tumor localization and evaluation of functional status.  Imaging is also 
commonly used to determine treatment outcome.  Gadolinium-enhanced magnetic 
resonance imaging (MRI) is the recommended method for the initial anatomic assessment 
of brain lesions.  MRI is preferred to computed tomography because of its superior soft 
tissue contrast which allows for more accurate assessments of lesions in the spine, 
brainstem, and cerebellum.  Magnetic resonance spectroscopy can also be used to provide 
metabolic and biochemical information about the tumor.   By pinpointing the cortical 
regions that control language, memory, and motor functions, functional MRI can be used 
for neurosurgical planning and neurologic risk evaluation.  Positron emission tomography 
(PET) is an important tool for evaluating the aggressiveness of the tumor and locating 
highly metabolic areas within the tumor.  PET can also be used during the follow-up 
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phase to evaluate the efficacy of treatment and to delineate tumor recurrence from 
radiation- induced necrosis.   
A biopsy of the tumor tissue will determine the diagnosis and the type of 
treatment required.  The choice to perform complete tumor resection depends on the 
location of the tumor. Complete resection is possible for some tumor types, however, the 
situation is complicated for high-grade gliomas such as GBM since tumor cells tend to 
migrate into the normal brain where they cannot be detected with current clinical imaging 
modalities. Since these cells are responsible for tumor recurrence, efforts must be devoted 
to find therapeutic approaches to eradicate these highly infiltrative cells. To that end, a 
number of local therapies, including photodynamic therapy (PDT) and photochemical 
internalization (PCI) have been proposed.   
After surgery, the standard treatment of high grade gliomas calls for external or 
internal radiation including highly conformal techniques such as stereotactic radio-
surgery.  Despite significant advances in radiation delivery devices, allowing for highly 
conformal treatments (and dose escalation), high-dose radiotherapy has had minimal 
impact on overall survival. This is probably due to the infiltrative nature of glioma cells, 
i.e., many of these cells have migrated into normal brain where the radiation dose is 
insufficient to eradicate them and hence, they form the locus of new tumors.  
 Delivery of drugs to the brain is complicated by the presence of the blood-brain 
barrier (BBB) which prevents most therapeutic agents (including chemotherapeutic 
compounds) from entering the brain. This poses a significant challenge for the 
eradication of infiltrating tumor cells. A number of different delivery methods have been 
attempted in order to address the difficulties posed by the BBB.  For example, drug-
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containing wafers have been placed in the surgical cavity after tumor removal and used in 
combination with radiation therapy.  Convection-enhanced delivery (CED) approaches 
have also been attempted.  Typically, CED uses multiple catheters implanted in the 
resection cavity following tumor removal. The chemotherapeutic agent is introduced into 
the resection cavity and brain adjacent to tumor via positive pressure infusion [Clarke 
2010].  The recent introduction of the chemotherapeutic agent, temozolomide, represents 
a significant development in the treatment of GBM since this drug has been shown to 
prolong overall survival by 2-3 months [Fadul 2008]. Due to its small molecular weight, 
TMZ efficiently crosses the BBB without significant adverse effects [Koukourakis 2009].   
 Due to the lack of efficacy of current GBM treatments, a wide variety of 
investigational therapies are currently being evaluated in both pre-clinical and clinical 
studies. For example, PDT is a localized laser-based treatment approach that has shown 
promise for the eradication of infiltrating glioma cells within a few cm of the resection 
margin [Mathews 2009].  
 
1.3 Photodynamic Therapy 
 PDT is based, in part, on the observation that photosensitizers show preferential 
accumulation in tumor cells. Light absorption at resonant wavelengths results in 
photosensitizer excitation and subsequent cytotoxicity.   Cytotoxicity is predominantly 
caused by a singlet oxygen-mediated reaction that causes damage to enzymes, plasma 
membranes, and cytoplasmic or nuclear organelles.  PDT dosimetry is complex as it 
depends on a number of parameters including photosensitizer concentration, light dose, 
dose rate, and oxygen concentration [Dubessy 2000].  A threshold dose is required in 
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order to induce cytotoxicity and this may be difficult to achieve in vivo due to a number 
of factors including limited light penetration in biological tissues and inadequate oxygen 
and photosensitizer concentrations in tumor tissues [Hogset 2004].   
PDT is initiated with the absorption of light by a photosensitizer which results in a 
transition to an electronically excited singlet state (Figure 3) [Berg 2005].  De-excitation 
to the ground state occurs with high probability and results in prompt emission of 
fluorescence. De-excitation to a triplet state via inter-system crossing occurs with low 
probability. The triplet photosensitizer can de-excite via type I or II mechanisms (Figure 
4). For the vast majority of photosensitizers, deactivation occurs primarily via a type II 
mechanism in which the excited triplet state sensitizer interacts with ground state triplet 
molecular oxygen resulting in the generation of singlet molecular oxygen – a strong 
oxidizing agent capable of causing significant damage to amino acids, unsaturated fatty 
acids, cholesterol, and guanine [Berg 2005].  
 
Figure 3. Jablonski diagram showing electronic states following absorption of 




   
Figure 4. Photochemical reaction pathways from the triplet state of a photosensitizer 
[Berg 2005]. 
 
Since singlet oxygen has a range of < 20 nm, the intended target must be close to 
the excited photosensitizer in order to be affected [Hogset 2004].  A good photosensitizer 
should have a high probability of triplet formation and the triplet state should be long-
lived in order to react with neighboring molecules [Berg 2005].  Depending on the 
photosensitizer and cell line, the photodynamic effects will lead to apoptosis, necrosis, or 
autophagy [Gupta 2010].  
 
1.4 Photochemical Internalization 
 PCI is designed to improve the use of macromolecules in cancer therapy in 
a site-specific manner [Dietze 2005]. The technique is summarized in Figures 5 and 6. 
PCI is a special version of PDT in which a plasma membrane localizing photosensitizer 
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and a macromolecule (e.g. bleomycin) is localized in endocytic vesicles of target cells 
(e.g. infiltrating glioma cells).  
 
Figure 5. An endocytic vesicle containing a photosensitizer and macromolecule  
undergoing PCI.  When light is incident on the vesicle, reactive oxygen species are 
formed, the membrane is broken and the macromolecule is released into the cytosol, but 







Figure 6. Illustration of PCI. A: Drugs enter cells via endocytosis and are 
transported to lysosomes where they are eventually degraded before serving their 
function.  B: Photosensitizer accumulates on endosome membranes and light exposure 
causes the membrane to rupture thus releasing the drug into the cytosol where it is free to 
diffuse to the target [Weyergang 2011]. 
 
Photosensitizers used in PCI must have a strong affinity for the plasma 
membrane. Such compounds will be incorporated into the membranes of endosomes and, 
following light activation, will result in the disruption of the membrane and subsequent 
release of the contents of the endosome. The photosensitizer must be excluded from the 
endosome interior in order to prevent damage to the contents of the endosome [Hogset 
2004]. 
Aluminum phthalocyanine disulfonate (AlPcS2a) is the most common 
photosensitizer used in PCI (Figure 7). Photosensitizers are characterized by their 
structure.  The efficiency and localization within the cell depends on how their polar and 




Figure 7. The chemical structure of aluminum phthalocyanine disulfonate (AlPcS2a) with 
two sulfonate groups on adjacent rings [Hogset 2004].  
 
AlPcS2a is a second generation amphiphilic photosensitizer with both hydrophilic 
and lipophilic domains [Bonneau 2004] and, as such, has excellent membrane penetrating 
properties, and high phototoxicity [Peng 1990].  Sulphonated aluminum phthalocyanine 
sensitizers are useful in PDT because of their stronger absorption at longer wavelengths 
of 650-800 nm [Ambroz 1990] where light penetration in biological tissues is optimal.  
Typically, the 670 nm absorption resonance is used in PCI applications.  Additionally, 
AlPcS2a has low absorption at other wavelengths, thus reducing the potential for skin 
photosensitivity [Gupta 2010]. 
The rapid attenuation of light in most tissues, including the brain, should lead to 
minimal side effects since the effect is localized to the irradiated area. The endosomal 
escape of macromolecules including genes, oligonucleotides and proteins by means of 
PCI has been documented both in vitro and in vivo and has been shown to increase the 
therapeutic effect in a synergistic manner [Dietze 2005, Selbo 2000].  Compared to other 
drugs, macromolecules (e.g. nucleic acids, peptides, proteins, and synthetic polymers) are 
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very specific when it comes to targeting [Hogset 2004].  The delivery of these 
macromolecules to targets within the cell is often problematic since their associated 
delivery vehicle (the endosome) is often degraded in lysosomes. Therefore, the 
macromolecules are often destroyed prior to reaching their target (e.g. the DNA in the 
nucleus). PCI solves this problem by releasing the macromolecules from the endosome 
prior to lysosomal degradation [Berg 2007].   
One benefit of using PCI is that there are no size restrictions for the delivery of 
molecules, such as chemotherapeutic agents [Hogset 2004].  PCI releases drugs that 
normally would be degraded in lysosomes thereby increasing the efficacy of the agent. 
Consequently, lower doses may be used thus minimizing the probability of adverse 
effects to the patient [Weyergang 2011].  PCI is limited by the penetration depth of light 
in biological tissues. For example, the penetration depth (e-1 intensity) of 670 nm light in 
brain tissues is approximately 2 mm. However, the low light fluences required for the 
PCI effect suggest that treatment depths of 1-2 cm should be possible [Hogset 2004]. 
This is significant since the majority of GBM tumors recur within 2 cm of the resection 
cavity [Wallner 1989]. 
 
1.5 Bleomycin    
Bleomycin (BLM) is a 1.5 kDa glycopeptic antibiotic that has been used in a 
number of chemotherapeutic regimens for the treatment of a variety of cancers including, 
squamous cell carcinomas of the head and neck, esophagus, bronchus, and skin, as well 
as Hodgkin’s and non-Hodgkin’s lymphoma [Dietze 2005].  BLM is water-soluble and 
was discovered in 1966 by Hamao Umezawa [Umezawa 1966].  BLM was originally 
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used as copper complexes from streptomyces verticillus [Roy 1984].  BLM has been used 
in brain tumor treatments since the early 1970’s and is delivered directly to the tumor 
since it does not pass through the intact BBB [Linnert 2009].  BLM is a mixture of eleven 
molecules that differ in their terminal amine part, which is involved in nucleic acid 
interactions.  BLM also has a glycannic part, a bithiazole moiety that binds to the DNA, 
and a pseudopeptidic area that binds transition metals and is used in sequence recognition 
(Figure 8) [Mir 1996].   
 
Figure 8. The structure of bleomycin [Stubbe 1986]. 
 
The molecule exerts its toxic effects by causing single and double-strand DNA 
breaks [Zaniboni 2005, Roy 1984].  Bleomycin induces single-strand and double-strand 
DNA breaks with a 10:1 ratio resulting in cell arrest in the G2-M phase.  In order to 
create these effects, BLM must pass through the cellular membrane and diffuse to the 
nucleus [Stubbe 1986].     
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BLM has a high intrinsic cytotoxicity, but since it cannot diffuse through the cell 
membrane, its capabilities are limited [Mir 1996].  Due to the limited penetration of BLM 
through the plasma membrane, tumor cells have a relatively low sensitivity to this anti-
cancer agent.  BLM enters cells via receptor-mediated endocytosis resulting in its 
encapsulation in endosomes.  Once in the cytosol, most endosomes end up in the 
lysosomes along with their contents (bleomycin).  Therefore, the vast majority of BLM 
never reaches the DNA [Pron 1999]. Due to its poor efficacy, BLM is typically used in 
combination with other agents [Mir 1996].      
 
1.6 Hyperthermia  
As a therapeutic procedure, hyperthermia produces elevated tissue temperatures 
resulting in impairment of cellular function.  Specifically, increased temperatures affect 
enzymatic and structural function within the cells.  This can affect cell growth, and lead 
to cell death via apoptosis and necrosis, depending on the temperature [Van der Zee 
2002].  Hyperthermia causes changes in the cell membrane that can reduce 
transmembrane transport and destabilize the cell’s potential [Dereski 1995].  
Additionally, hyperthermia can result in inhibition of nucleic acid synthesis, and enzyme 
repair, and changes in DNA conformality [Van der Zee 2002].  From a therapeutic 
perspective, tumor cells are less resistant to sudden increases in temperature than normal 
cells. 
Temperature increases can be achieved by different techniques including 
microwaves, radiofrequency, ultrasound, or electrically- induced methods.  All of these 
approaches have yielded good results, but there is still the problem of obtaining 
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homogeneous temperature distributions throughout large tumors.  Failure to achieve 
adequate temperature elevations throughout the tumor results in recurrence, whereas 
overheating can result in undesirable inflammatory responses [Silva 2011].  Superficial 
tumors are excellent candidates for hyperthermia since they can be treated noninvasively 
via surface irradiation [Zhao 2011].   
Heat therapy has been used for twenty years and has been shown to result in local 
control for a number of tumor types [Zhao 2011].  Hyperthermia has been used alone and 
in combination with other treatments [Dereski 1995].  Hyperthermia-induced cytotoxicity 
depends on both temperature and heating time.  Hyperthermia occurs at temperatures 
between 40 and 44˚C, which is cytotoxic for tumor cells due to insufficient blood 
perfusion via the tumor vasculature [Van der Zee 2002].  For optimum effect, the 
elevated temperatures are typically maintained over a period ranging from 30 to 60 min. 
Due to impaired blood flow, tumors have reduced thermoregulatory abilities resulting in 
preferential heating during hyperthermia. Furthermore, reduced blood flow results in 
deprivation of oxygen and nutrients to tumors making them more heat sensitive [Field 
1979].  Hyperthermia is a strong sensitizer of radiotherapy and a number of cytotoxic 
drugs: combination therapies consisting of hyperthermia and radiotherapy or 
chemotherapy have been shown to produce additive effects, as long as the treatments are 
administered without a significant time gap. Hyperthermia likely enhances the effects of 
chemotherapy by increasing tumor perfusion resulting in increased drug delivery [Van 
der Zee 2002].      
The limiting factor in chemotherapeutic treatment regimens is drug toxicity. 
Previous experiments with murine tumors have shown positive results by using radiation, 
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chemotherapy, and hyperthermia in different combinations.  For example, hyperthermia 
in combination with bleomycin increased cell death and tumor regression [Rao 2010].  
The chemotherapy-hyperthermia combination has also shown improvement of survival 
rates and quality of life in patients [Zhao 2011].  Previous studies have shown that 
exposing cells to high temperatures can alter the fluidity of the cellular membrane and 
inhibit protein synthesis.  Hyperthermia can also destroy enzymes involved in DNA 
synthesis and cause cytotoxic effects.  These effects can lead to structural alterations in 
biological macromolecules, increase oxygen concentrations in the cell, affect material 
transport, and alter energy conversion.  Many studies have also shown that hyperthermia 
leads to apoptosis [Zhao 2011]. 
PDT has been used in combination with hyperthermia both in vivo and in vitro.  
For example, Dereski et al (1995) found that the effects were greater than additive when 
hyperthermia was given post-PDT.  Hyperthermic temperatures were found to inhibit 
repair of sub- lethal damage thereby making hypoxic cells more sensitive to PDT.  Using 
a murine mammary adenocarcinoma model, Chen et al (1996) showed that the 
combination of PDT and hyperthermia produced a synergetic tumor response.  
Hirschberg et al, (2004) examined synergistic effects of 5-aminolevulinic acid-mediated 
PDT and hyperthermia concurrently on human and rat glioma spheroids.  The results 
showed that, when administered separately, PDT and hyperthermia were not very 
effective, however, concurrent administration of the two treatment modalities resulted in 





1.7 Multicellular Tumor Spheroids 
A spheroid is an in vitro tumor model that has some characteristics of in vivo 
tumors [Dubessy 2000].  Multicellular tumor spheroids (MCTS) are three-dimensional 
collection of cells that mimic small tumors and metastases.  MCTS have cellular 
heterogeneity which is a property of most solid tumors [Mueller-Klieser 2000].  The 
biological behavior of spheroids and their shape are similar to tumor nodules and they are 
therefore more representative of an in vivo situation than monolayer cell cultures. MCTS 
represent an excellent model for the initial evaluation of experimental therapies 
[Hirschberg 2004].   
 Spheroids are formed from the aggregation of multiple clonogenic cells.  The 
cells proliferate exponentially and are weakly bound together.  After a few hours, a 
critical cell density is reached and the spheroid becomes reinforced by intercellular links 
such as gap junctions and desmosomes [Dubessy 2000]. 
  
Figure 9. The pathway spheroids undergo when cells move from the viable outer surface 




   As illustrated in Figure 9, cells are stratified into three layers according to 
oxygen, pH and nutrient gradients: an outer proliferative layer that is in contact with a 
nutrient-rich medium, a non-proliferative layer lacking in oxygen and nutrients and a 
necrotic core consisting of dead cells.  Due to the limited diffusion of oxygen and 
nutrients, a necrotic core develops when the spheroid reaches a diameter of 200-500 µm. 
[Dubessy 2000].  Since MCTS are cultured from genetically stable cell lines, the 
structure can be reproduced.  This allows for reproducibility of growth kinetics, diameter 
of the necrotic center, and viable rim of cells over multiple experiments.  The necrotic 
core typically grows at a similar rate as the viable outer surface [Mueller-Klieser 2000].  
The size of necrosis varies by spheroid diameter, cell line, oxygen gradient, pH, and 
nutrients [Dubessy 2000].  Spheroid viability can be determined by measuring its volume 
or by measuring the necrotic center or viable rim thickness.   
 The ability of spheroids to mimic oxygen gradients found in tumor nodules in 
vivo makes them ideally suited for investigational studies involving oxygen-dependent 
therapies such as PDT and ionizing radiation.  In this respect, the non-proliferating 
quiescent cells in hypoxic regions of spheroids are particularly relevant since they 
represent a cell population resistant to oxygen-dependent therapies. The efficacy of a 
therapy is critically dependent on its ability to eradicate these cells. The primary 
disadvantage of MCTS is their inability to model tumor vasculature. Additionally, MCTS 
lack the cellular heterogeneity of tumors in vivo as well as a functioning immune system 
[Madsen 2006]. 
Not surprisingly, studies show that MCTS are less sensitive to PDT than 
monolayers.  As the size of the spheroid increases, the sensitivity to PDT decreases. 
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These observations can be explained in terms of oxygen availability. For example, cells 
in monolayers are well oxygenated whereas a significant fraction of cells in spheroids are 
located in hypoxic areas and therefore exhibit an increased resistance to oxygen-mediated 
therapies such as PDT.  Uneven photosensitizer distributions in spheroids are also a 
contributing factor to their increased PDT resistance compared to monolayers [Dubessy 
2000]. 
 
1.8 Scope of Study 
 
 The overall objective of the proposed work is to determine whether hyperthermia 
increases the efficacy of PCI-mediated delivery of bleomycin in an in vitro model 
consisting of human glioma spheroids. It is hypothesized that PCI, performed under 
hyperthermic conditions, will increase the efficacy of bleomycin as determined from 
spheroid survival and growth kinetics. Furthermore, it is hypothesized that, under 
appropriate light irradiation and temperature levels, the interaction between PCI and 
hyperthermia is synergistic rather than additive.  






MATERIALS AND METHODS 
 
 
2.1 Cell Line 
All cell line manipulations were performed in a Labconco Purifier Class A2 
Biological Safety Cabinet at the University of Nevada, Las Vegas.  The human glioma 
cell line (ACBT; University of California, Irvine) was obtained from biopsy. Cells were 
incubated at 37˚C, 5.0% CO2, and 95% humidity inside a Shell Lab CO2 Series incubator.  
The cell line was kept in Gibco Dulbecco’s Modified Eagle Medium (DMEM) High 
Glucose 1X with 10% heat- inactivated fetal bovine serum (FBS), 25mM HEPES buffer 
(pH 7.4), penicillin (100U/ml), and streptomycin (100 µg/mL).  The monolayer cells 
were passed twice a week using the same procedure.  The confluency of the flask was 
noted prior to washing with 5mL of Gibco phosphate buffered saline (PBS) with pH of 
7.2 and emptied of any remaining media.  Next, 1 mL of Gibco 0.25% Trypsin-EDTA 
was added to the flask and left to sit for 5 minutes.  Trypsin is a proteolytic enzyme that 
allows the ACBT cells to detach from the bottom of the flask.  After 5 minutes, the flask 
was tapped against the lab cabinet to help detach any cells remaining in the flask.  Then, 
4 mL of DMEM was added to the flask and pipetted up and down and transferred to a 15 
mL centrifuge tube.  In order to maintain the cell line, 500 uL was added to 4.5 mL of 






2.2 Spheroid formation 
Spheroids were formed using a modified centrifugation method first described by 
Ivascu and Kubbies [2006]. Briefly, 5,000 ACBT cells were detached from the growth 
flask; the exact number of cells was determined from coulter counting. The cells were 
pipetted into one well of a 96-well plate. Each round bottomed well was coated with 
matrigel and the plate was centrifuged at 1000g for 10 min.  Following centrifugation, the 
well plate was placed in a CO2 incubator for 48 h to allow them to take on the usual 3-
dimensional spheroid morphology.   
2.3 PDT and PCI treatments  
After 48 hours, the resultant 350-400 µm diameter spheroids were transferred 
from the 96-well plate to 35 mm irradiation dishes where they were incubated in 1 µg/mL 
AlPcS2a for 18 h at 37 
oC and 5% CO2.  Following incubation, spheroids were washed 
and placed into new medium. Spheroids in the PCI group were then subjected to an 
additional incubation in 0.25 µg/mL of bleomycin for 4 h. Following incubation, 
spheroids in both PDT and PCI groups were irradiated with a photodiode laser 
(wavelength = 670 nm) coupled to a 200 µm diameter optical fiber fitted with a micro-
lens. In all cases, spheroids were subjected to an irradiance of 5 mW cm-2 for a range of 
times required to deliver radiant exposures ranging from 0.5 to 3.0 J cm-2.  All 
irradiations were performed at 37 oC in a temperature controlled incubator. This was 
accomplished by inserting the laser-coupled optical fiber through a small aperture located 
at the top of the incubator.   
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 Following light exposure, 16 spheroids from each dish were placed into separate 
wells of an agarose coated Costar 48-well plate containing 750 µL of DMEM.  Spheroid 
growth kinetics were monitored by recording two orthogonal diameters of each spheroid 
using a microscope with a calibrated eyepiece micrometer. Spheroid growth was 
measured 24 h after treatment and then twice a week over a 29-day period.  After each 
measurement, 400 µL of DMEM was removed and replaced with 400 µl of fresh DMEM 
to provide the spheroids with adequate nutrients.  
2.4 Hyperthermia  
 The 35 mm dishes containing medium and spheroids were placed in a temperature 
controlled incubator for 40-50 min. at temperatures ranging from 40o to 50o C. In the case 
of the combined treatments (PDT + HT; PCI + HT), spheroids were placed in the 
incubator 40 min. prior to light irradiation. Irradiances and radiant exposures were 
identical to those described previously. Following treatment, spheroids were placed in a 
48-well plate and monitored as previously described. In all cases, the temperature of the 
incubator was monitored using a standard laboratory thermometer.      
2.5 Statistical Analysis  
 All data were analyzed and graphed using Microsoft Excel.  The two orthogonal 
diameter averages were used to calculate the average diameter of the spheroids.  Each 
experiment included around 16 spheroids per group and was repeated 2-3 times and the 
average volume was calculated (V = 4/3 πr3).  Standard errors were used throughout to 
calculate the error bars. 
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 The degree of interaction between PCI and hyperthermia was evaluated according 
to the method of Drewinko et al. (1976). In this scheme the degree of interaction is given 
by 
                                                     
            
        
                                          (1) 
where SFPCI and SFHT  represent the surviving fractions following PCI and hyperthermia, 
respectively, and SFPCI+HT  is the surviving fraction after combined treatments. In this 
analysis, α = 1 indicates an additive effect (or absence of any effect), α > 1 indicates a 



















3.1  Radiant exposure of 0.5 J cm-2  
3.1.1  37˚C and 50˚C  
 Based on results from previous in vitro PCI studies, an initial radiant exposure of 
0.5 J cm-2 was chosen.  The purpose of the initial set of experiments was to: (1) evaluate 
the efficacy of very low light exposures, and (2) determine the hyperthermic threshold for 
this particular in vitro model.  In order to avoid data clutter, the three control curves at 
physiological temperature have been plotted in Figure 10. The control groups show 
similar growth kinetics over the 29-day observation period. At the time of irradiation (day 
0), spheroid diameters ranged from 350-400 µm.  ACBT spheroids typically reach a 
growth plateau at diameters ranging from 1100-1500 µm which, in these studies, 
occurred approximately four weeks following irradiation, thus providing the rationale for 




Figure 10. Average spheroid volume over a 29-day period at 37˚C for control groups.  
The true control group (no treatment) is denoted by Control, while Dark Control and 




The data in Figure 11 show complete growth inhibition of all spheroids (control and 
treatment groups) subjected to 50 oC for 50 min.  Clearly, lower temperatures must be 
chosen.  No significant differences in growth kinetics between the PCI and PDT groups 
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Figure 11. Average spheroid volume over a 29-day period at 37and 50˚C. 


































Days Post Treatment 
Spheroid Volume vs. Time After 
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Control 50 
Dark Control 50 
BLM 50 
PDT 0.5J 37 
PCI 0.5J 37 
PDT 0.5J 50 
PCI 0.5J 50 
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3.1.2 40˚C and 45˚C  
 
Figure 12. Average spheroid volume over a 29-day period for control groups at 40 and 
45˚C. 
 
At temperatures of 45oC, all controls showed significant growth inhibition 
compared to spheroids subjected to 40oC (Figure 12). These results suggest that the 
threshold for complete heat- induced cell death occurs somewhere between 40 and 45oC. 
As illustrated in Figure 13, no significant differences were observed between the PDT 
and PCI groups at 40 oC suggesting that a higher radiant exposure is required. Not 
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Figure 13. Average spheroid volume over a 29-day period at 40˚C and 45˚C. 
 
3.1.3 42˚C 
 The data in Figure 14 show that spheroids in both treatment and control groups 
were growing throughout the observation period. No significant growth differences were 
observed between spheroids in the two treatment groups and between spheroids in the 
control and treatment groups. Again, this is highly suggestive of inadequate light 
exposure levels. The data in Figures 12-14 show that the threshold for complete heat-
induced cell death occurs somewhere between 42 and 45oC. For this reason, a 
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Figure 14. Average spheroid volume over a 29-day period at 42˚C. 
 
3.2 Radiant exposure of 1.0 J cm-2  
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As shown in Figure 15, radiant exposures of 1.0 J cm-2 failed to produce 
significant differences in the growth kinetics of spheroids subjected to PCI at the two 
temperatures investigated. Even at this low light level, significant growth differences 
were observed between PCI- and PDT-treated spheroids at both temperatures. This 
suggests that the observed effect is not attributable to PDT.  
  
3.3 Radiant exposure of 1.5 J cm-2  
PCI and PDT at 40 oC resulted in a statistically significant reduction in survival 
compared to controls (Figure 16). At 37 oC, neither treatment was effective, resulting in 
100% survival (data not shown).  The alpha coefficient (from equation 1) was found to be 
1.4 suggesting a relatively low degree of synergism between 1.5 J PCI and 40 oC. 
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Figure 17. Average spheroid volume over a 29-day period at 1.5 J cm-2 for 37 and 40˚C. 
 
 The data in Figure 17 show that PDT and PCI at 1.5 J cm-2 were more effective 
than treatments at the lower light levels. For both temperatures investigated, PCI induced 
greater growth inhibition than PDT.  Both PDT and PCI were more effective at the higher 
temperature thus illustrating the therapeutic advantage conferred by hyperthermia.  The 
effectiveness of combined PCI and hyperthermia at 1.5 J cm-2 can be appreciated by 
comparing the final spheroid volume (ca. 0.5 mm3) to the final volume obtained for the 
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3.4 Radiant exposure of 2.5 J cm-2
  
Figure 18. The percentage of viable spheroids over four weeks for 37˚C and 42˚C at 2.5 J 
cm-2. The Dark/BLM Control group represents spheroids incubated in AlPcS2a for 18 h 
followed by a 4 h incubation in bleomycin (no light treatment).  
 
 PDT and PCI treatments at a radiant exposure of 2.5 J cm-2 resulted in spheroid 
toxicity significantly higher than observed at the lower light levels. This was particularly 
the case for the PCI treatments where survivals of approximately 43 and 10 % were 
observed at temperatures of 37 and 42oC, respectively (Figure 18). The α coefficient (4.3) 
suggests a significant degree of synergism between PCI and hyperthermia (42 oC) at this 
radiant exposure.  The enhanced efficacy at 2.5 J cm-2 is also evident from the growth 
kinetics data in Figures 19 and 20. Of particular relevance is the combined PCI – 
hyperthermia data in Figure 20 showing almost complete spheroid growth inhibition as 
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Figure 19. Average spheroid volume over a 29 day period for 37˚C at 2.5J cm-2.  
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3.5 Radiant exposure of 3 J cm-2  
 Complete growth inhibition was observed in all treatment groups, even at 
physiological temperatures (37˚C; Figure 21). The data suggest that this light level was 
too high.  
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 PCI is a specialized application of PDT that may be used to enhance the delivery 
of macromolecules including chemotherapeutic agents such as bleomycin. This 
therapeutic modality is appealing for a number of reasons including: (1) the lack of size 
restrictions on the therapeutic molecules to be delivered, (2) high site specificity which 
confines the biological effect to light- illuminated volumes thus minimizing side effects of 
the drug, (3) increased therapeutic efficacy of a wide range of macromolecules allowing 
for the possibility of lower drug doses resulting in decreased morbidity, (4) high 
suitability for combination with other strategies for targeted drug delivery, thereby 
increasing the potential for further therapeutic improvements [Berg 1999; Dietze 2005; 
Selbo 2001;  Selbo 2010; Weyergang 2011]. 
 Although PCI has been investigated in a variety of cancer models, the particular 
emphasis of this thesis was the treatment of high grade gliomas such as GBM. These 
tumors pose a significant therapeutic challenge: due to their diffuse and infiltrative 
nature, complete surgical resection is virtually impossible. The propensity of glioma cells 
to migrate along white matter tracts suggests that a cure is possible only if these 
migratory cells can be eradicated. The observation that 80% of GBMs recur within 2 cm 
of the resection cavity [Wallner 1989] suggests that the development of local therapies 
may prove to be an effective strategy for the eradication of glioma cells in the resection 
margin, or brain-adjacent-to-tumor (BAT). Unfortunately, the delivery of therapeutic 
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agents to the BAT is complicated by variations in the patency of the BBB which is leaky 
in some regions and intact in others [Madsen 2010]. The BBB controls the passage of 
blood-borne agents into the central nervous system and, as such, it plays a vital role in 
protecting the brain against pathogens. Although this protective mechanism is essential 
for normal brain function, it also poses a significant hindrance to the entry of drugs into 
the brain. The protective function of the BBB is especially problematic for the treatment 
of infiltrating gliomas. Although surgery is used to remove gross tumor, standard 
adjuvant therapies consisting of radiation and chemotherapy have proven inadequate for 
eradicating infiltrating cells in the BAT. In the case of chemotherapeutic drugs, this is 
due to their inability to penetrate the intact BBB. Therefore, elimination of glioma cells in 
the BAT is unlikely to be accomplished until methods are developed to: (1) deliver drugs 
or carriers across the BBB at selected sites, or (2) selectively disrupt the BBB [Madsen 
2010].  
 Selective disruption of the BBB by either PDT or PCI may prove useful for 
enhancing the delivery of therapeutic agents for the treatment of a variety of brain 
diseases including cancer. Localized opening of the BBB has been accomplished using a 
number of techniques including ultrasound [Vykhodtseva 2008] and laser-based 
approaches such as PDT [Hirschberg 2008] and PCI [Hirschberg 2009]. These methods 
are appealing due to the highly localized nature of the BBB disruption: in contrast to the 
use of hyperosmolar solutions, the BBB is only disrupted at sites subjected to sufficient 
laser power densities which can be controlled by the user to coincide with the location of 
the pathology. Through careful choice of beam parameters, the targeted volume can be as 
small as a few mm3. Of particular interest are observations showing that these highly 
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focused approaches do not cause permanent damage to the BBB, as long as incident 
power densities remain below threshold levels [Hirschberg 2009]. Under these 
conditions, the BBB may remain open for relatively long periods of time thus facilitating 
multi- fractionated drug delivery.  
 Selective disruption of the BBB via PCI-mediated delivery of Clostridium 
perfringens epsilon prototoxin (Clp) was recently demonstrated in Fischer rats 
[Hirschberg 2009]. Clp was chosen due to the ability of active toxin to cause widespread 
and reversible opening of the BBB [Worthington 1975; Nagahama 1991; J. Dorca-
Arevalo 2008].  Following systemic administration, Clp prototoxin is converted to active 
toxin via proteolytic cleavage. The results demonstrated that Clp-PCI was capable of 
causing localized BBB disruption at very low light fluences (1 J). Based on magnetic 
resonance images, maximum BBB opening occurred 3 days following PCI and pathology 
analyses revealed no permanent BBB damage at these low light levels.  
 In a follow-on study, using an orthotopic brain tumor model consisting of F98 
glioma cells in Fischer rats, newly implanted tumor cells were used to mimic the 
characteristics of infiltrating cells in the resection margin usually found following 
surgical removal of gross tumor [Madsen 2006]. PDT- or PCI- localized BBB opening 
was performed 24 h following cell inoculation.  This is an insufficient time to allow for 
the development of bulk tumor and BBB degradation, but long enough for the cells 
(doubling time of approximately 18 h) to form small, sequestered, micro-clusters which 
are protected by an intact BBB. The survival of animals implanted with F98 tumor cells  
was significantly extended following BLM chemotherapy with PCI-mediated BBB 
opening compared to controls that received chemotherapy only.    
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 As has been shown, the BBB presents a significant obstacle to the delivery of 
chemotherapeutic agents, such as bleomycin, to glioma cells residing in the BAT. 
Endosomal entrapment is another factor limiting the efficacy of bleomycin and it was this 
problem that was addressed in this thesis. PCI-mediated delivery of bleomycin has been 
investigated in glioma spheroids [Mathews (in press)] and the results are in qualitative 
agreement with the findings of this work, i.e., at sufficient radiant exposures (1.5 J cm-2) 
PCI enhances the efficacy of bleomycin as demonstrated by decreased spheroid survival 
and reduced growth kinetics compared to PDT controls. In the previous study, PCI was 
examined at relatively low light levels (≤ 1.5 J cm-2) and all studies were performed at 
physiological temperatures (37oC). The studies performed in this thesis extend the 
previous work by examining the effects of higher light doses and, most importantly, the 
combination of PCI and hyperthermia.  
 The exact hyperthermic threshold, i.e., the temperature resulting in a significant 
diminution in spheroid survival was somewhat difficult to ascertain due to inaccuracies in 
the thermoregulatory capabilities of the incubator in which the cells were irradiated. 
Based on temperature readings during the exposures, the incubator was deemed accurate 
to 1.0 degrees C. Based on the data presented in Figures 12 and 14 all control spheroids 
were viable at 42 oC while almost all were dead at 45 oC thus suggesting a threshold close 
to 45o. This is in qualitative agreement with the results of Hirschberg et al. [Hirschberg 
2004] who observed significant hyperthermia- induced glioma spheroid death at 
temperatures between 46 and 49oC. The slight differences between experiments may be 
due to differences in spheroid formation techniques (agar overlay method vs. 
centrifugation) which produce slight variations in spheroid morphology.  From the results 
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presented in Figs. 12 and 14, it was decided to use a temperature of 42oC for the majority 
of studies. This has significant clinical relevance since many patients undergoing 
hyperthermia or combined hyperthermia therapies are treated at this temperature. In 
future studies, the use of calibrated thermocouples immersed directly in the cell medium 
would be a more accurate method of determining the temperature compared to the 
technique used in the present work, i.e., the measurement of air temperature using 
thermometers. 
 Of particular relevance are the results showing that hyperthermia can enhance the 
effects of PCI-mediated delivery of bleomycin (Figs. 16-18, 20). The degree of 
interaction between the two modalities was found to be critically dependent on light dose: 
no effect was observed at radiant exposures below 1.5 J cm-2, while low and high degrees 
of synergism were observed at 1.5 and 2.5 J cm-2, respectively. This is the first 
observation of a synergistic interaction between PCI and hyperthermia.  
 Although the mechanism of synergism between PCI and hyperthermia is 
unknown, it likely has several components. For instance, it might be due, in part, to 
thermally- induced inhibition of DNA repair enzymes [Van der Zee 2002]. Bleomycin 
produces DNA damage and this damage is likely exacerbated if the function of repair 
enzymes is inhibited by hyperthermia. Additionally, hyperthermia is known to cause 
damage to cellular membranes [Silva 2011] and, by implication, to endosomal 
membranes. Subsequently, these heat-damaged membranes may be more susceptible to 









The overall objective of the proposed work was to determine whether 
hyperthermia increases the efficacy of PCI-mediated delivery of bleomycin in an in vitro 
model consisting of human glioma spheroids. The results show that hyperthermia and 
PCI interact in a synergistic manner over a very narrow range of light and temperature 
levels. A temperature of 45 oC resulted in total spheroid death, while all spheroids 
subjected to 42 oC survived. Therefore, the hyperthermic threshold was estimated to be 
between 42 and 45 oC. This provided the rationale for the temperature range investigated 
(40 – 42 oC). No significant differences in growth kinetics and survival were observed 
between PCI- and PDT -exposed spheroids at radiant exposures < 1.5 J cm-2. In contrast, 
all PDT and PCI spheroids irradiated with 3.0 J cm-2 died, suggesting that the useful light 
range is between 1.5 and 3.0 J cm-2.  
The experiments show that hyperthermia enhanced the PCI-mediated delivery of 
bleomycin. A relatively low degree of synergism (α=1.4) was observed between PCI and 
hyperthermia at 1.5 J cm-2 and 40 oC, while a high degree of synergism (α=4.3) was 
found when the two modalities were combined at a light level of 2.5 J cm-2 and a 
temperature of 42 oC. This represents the first observation of a synergistic interaction 
between PCI and hyperthermia. 
Future experiments should consider a better temperature monitoring technique.  
By using a thermocouple immersed directly in the cell solution, the temperature can be 
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monitored more accurately.  Additional experiments might also examine radiant 
exposures of 2 J cm-2 to determine if the radiant exposure can be limited further to spare 
as many healthy cells as possible.  Overall, the results provide the basis for additional in 
vivo experiments which could be performed using well established orthotopic rat brain 
tumor models.  
Other experiments should examine the mechanisms underlying the observed 
synergism between the two treatment modalities. One possibility is that hyperthermia 
inhibits DNA repair enzymes. It was also postulated that hyperthermia can cause damage 
to cellular or endosomal membranes, thus resulting in an enhanced release of bleomycin 
in PCI.  This could be examined by measuring intracellular concentrations of bleomycin 
as a function of temperature. Valuable insight into the mechanisms of synergism might be 
gained from studying the mode of cell death (apoptosis vs. necrosis) following combined 
treatments. Such studies would be relatively straightforward in the human glioma 
spheroid model used in this work.  
Finally, the efficacy of hyperthermia and PCI should be investigated in different 
types of cancer cell lines in order to determine the overall utility of this combination 
therapy. A logical starting point would be to use spheroids since they can be formed from 
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